Identification

Name
Dalteparin
Accession Number
DB06779
Type
Small Molecule
Groups
Approved
Description

Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Synonyms
  • alpha-heparin
Product Ingredients
IngredientUNIICASInChI Key
Dalteparin sodium12M44VTJ7BNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FragminSolution25000 unitIntravenous; SubcutaneousPfizer1997-11-27Not applicableCanada
FragminInjection10000 [iU]/.4mLSubcutaneousEisai Limited1994-12-222017-02-10Us
FragminInjection15000 [iU]/.6mLSubcutaneousPfizer Laboratories Div Pfizer Inc.2015-04-01Not applicableUs
FragminInjection2500 [iU]/.2mLSubcutaneousPfizer Laboratories Div Pfizer Inc.2015-04-01Not applicableUs
FragminInjection5000 [iU]/.2mLSubcutaneousEisai Limited1994-12-222017-02-10Us
FragminSolution18000 unitIntravenous; SubcutaneousPfizer2011-02-01Not applicableCanada
FragminInjection18000 [iU]/.72mLSubcutaneousEisai Limited1994-12-222017-02-10Us
FragminSolution10000 unitIntravenous; SubcutaneousPfizer1995-12-31Not applicableCanada
FragminSolution10000 unitIntravenous; SubcutaneousPfizer2011-02-01Not applicableCanada
FragminInjection10000 [iU]/mLSubcutaneousEisai Limited1994-12-222017-02-10Us
International/Other Brands
Boxol (Pharmacia) / Eurodal (Gland) / Ligoframin (Pfizer) / Low Liquemine (Roche)
Categories
UNII
S79O08V79F
CAS number
9005-49-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications.

Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).

It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.

Associated Conditions
Pharmacodynamics

Dalteparin has an antithrombin binding site that is essential for high affinity binding to the plasma protein antithrombin (ATIII). Anti-Xa activity of plasma is used as both as an estimate of clotting activity, and as a basis to determine dosage. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.

Mechanism of action

Dalteparin potentiates the activity of ATIII, inhibiting the formation of both factor Xa and thrombin. The main difference between dalteparin and unfractionated heparin (UH) is that dalteparin preferentially inactivates factor Xa. As a result, only a slight increase in clotting time [(i.e. activated partial thomboplastin time (APTT)] is observed relative to UH. For this same reason, APTT is not used to monitor the effects of dalteparin except as an indicator for overdosage.

TargetActionsOrganism
AAntithrombin-III
potentiator
Human
AVascular endothelial growth factor A
inhibitor
Human
ATissue factor pathway inhibitor
inhibitor
Human
UP-selectin
inhibitor
Human
Absorption

Almost completely absorbed after subcutaneous (sc) doses, with a bioavialability of about 87%.

Volume of distribution

3 litres

Protein binding

Less than unfractionated heparin, which is more than 90%.

Metabolism

Liver and the reticulo-endothelial system are the sites of biotransformation. They are partially metabolized by desulphatation and depolymerization.

Route of elimination

After 4 hours, about 20% is seen in urine. Most of the remainder is found in the liver, gastrointestinal tract and kidney. The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).

Half life

Terminal Half life: Intravenous - 2 hours. Subcutaneous - 3-5hours

Clearance

Excreted via kidneys. The plasma clearance rate is 33 mL/min.

Toxicity

Overdosage: hemorrhagic complications. Adverse Drug Reaction: (common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia. (uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Dalteparin.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Dalteparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Dalteparin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Dalteparin.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
AliskirenDalteparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Dalteparin.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Dalteparin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Dalteparin.Approved
AltrenogestThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Altrenogest.Vet Approved
AmikacinThe therapeutic efficacy of Amikacin can be decreased when used in combination with Dalteparin.Approved, Investigational, Vet Approved
AmilorideDalteparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dalteparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Dalteparin.Approved
AncrodAncrod may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Dalteparin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Dalteparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Dalteparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Antithrombin III humanDalteparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Dalteparin.Approved
ApocyninApocynin may increase the anticoagulant activities of Dalteparin.Investigational
ApremilastApremilast may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AprotininThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Dalteparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Dalteparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Dalteparin.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Dalteparin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilDalteparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Dalteparin.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Dalteparin.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Dalteparin.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Dalteparin.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Dalteparin.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Dalteparin.Approved
BeraprostBeraprost may increase the anticoagulant activities of Dalteparin.Investigational
BevoniumBevonium may increase the anticoagulant activities of Dalteparin.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Dalteparin.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Dalteparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Dalteparin.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Dalteparin.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Dalteparin.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Dalteparin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Dalteparin.Investigational
CanagliflozinDalteparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanDalteparin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilDalteparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CangrelorCangrelor may increase the anticoagulant activities of Dalteparin.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Dalteparin.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Dalteparin.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved, Withdrawn
CarvedilolThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the anticoagulant activities of Dalteparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
CertoparinDalteparin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlormadinoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Chlormadinone.Experimental
ChloroquineChloroquine may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Dalteparin.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Dalteparin.Approved
CilostazolCilostazol may increase the anticoagulant activities of Dalteparin.Approved, Investigational
ClonixinClonixin may increase the anticoagulant activities of Dalteparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Dalteparin.Approved
CloricromenCloricromen may increase the anticoagulant activities of Dalteparin.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Dalteparin.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Dalteparin is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Dalteparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
CyclosporineThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Dalteparin.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Dalteparin.Experimental
DanaparoidDanaparoid may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
DarexabanDalteparin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Dalteparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
DemegestoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Demegestone.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dalteparin is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Dalteparin.Investigational
DesirudinDalteparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Dalteparin.Investigational
DesogestrelThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Dalteparin.Approved, Investigational
DextranDalteparin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacThe risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Dalteparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Dalteparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Dalteparin.Approved, Investigational
DienogestThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Dalteparin.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Dalteparin.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Dalteparin.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Dalteparin.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Dalteparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Dalteparin.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Dalteparin.Investigational
DydrogesteroneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Dalteparin.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Dalteparin.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Dalteparin.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Dalteparin.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Dalteparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Dalteparin.Approved
EplerenoneDalteparin may increase the hyperkalemic activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Dalteparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Dalteparin.Approved
EprosartanDalteparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Dalteparin.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Dalteparin.Approved
EstroneEstrone may decrease the anticoagulant activities of Dalteparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Dalteparin.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Dalteparin.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Dalteparin.Approved
Ethyl biscoumacetateDalteparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Dalteparin.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Dalteparin.Investigational, Nutraceutical
ExisulindExisulind may increase the anticoagulant activities of Dalteparin.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Dalteparin.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Dalteparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Dalteparin.Approved
FentiazacFentiazac may increase the anticoagulant activities of Dalteparin.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Dalteparin.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Dalteparin.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Dalteparin.Investigational
FimasartanDalteparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
FluindioneDalteparin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Dalteparin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Dalteparin.Experimental
FluoxetineFluoxetine may increase the antiplatelet activities of Dalteparin.Approved, Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Dalteparin.Approved, Investigational
FluvoxamineFluvoxamine may increase the antiplatelet activities of Dalteparin.Approved, Investigational
FondaparinuxFondaparinux sodium may increase the anticoagulant activities of Dalteparin.Approved, Investigational
ForasartanDalteparin may increase the hyperkalemic activities of Forasartan.Experimental
FosinoprilThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Fosinopril.Approved
GabexateDalteparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Dalteparin.Investigational
GestodeneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Dalteparin.Experimental
HeminHemin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Dalteparin.Experimental
HeparinHeparin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Dalteparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Dalteparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Dalteparin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dalteparin is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dalteparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Dalteparin.Approved, Investigational
IbuprofenThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Dalteparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Dalteparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Dalteparin.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Dalteparin.Investigational
IloprostIloprost may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Dalteparin.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Dalteparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Dalteparin.Withdrawn
IrbesartanDalteparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Dalteparin.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Dalteparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Dalteparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
KetorolacThe risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Dalteparin.Approved
LabetalolThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Labetalol.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
LepirudinDalteparin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDalteparin may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelLevonorgestrel may decrease the anticoagulant activities of Dalteparin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dalteparin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Dalteparin.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Dalteparin.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Dalteparin.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Dalteparin.Approved, Investigational
LosartanThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Dalteparin.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
LynestrenolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Lynestrenol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Dalteparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Dalteparin.Approved
Megestrol acetateThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranDalteparin may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Dalteparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Dalteparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Dalteparin.Experimental
Methyl salicylateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Dalteparin.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Methylestrenolone.Experimental
MetoprololThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Metoprolol.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Dalteparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Dalteparin.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Dalteparin.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Dalteparin.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Dalteparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Dalteparin.Approved
NadroparinDalteparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Dalteparin.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Dalteparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Dalteparin.Investigational
NaproxenThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dalteparin.Approved, Vet Approved
NeomycinThe therapeutic efficacy of Neomycin can be decreased when used in combination with Dalteparin.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Dalteparin.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Dalteparin.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Dalteparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Dalteparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Dalteparin.Investigational
NomegestrolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Dalteparin is combined with Obinutuzumab.Approved, Investigational
OlmesartanDalteparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Dalteparin.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Dalteparin.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Dalteparin is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Dalteparin.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Dalteparin can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Dalteparin.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Dalteparin.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Dalteparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Dalteparin.Investigational
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Dalteparin.Approved
PalmidrolPalmidrol may increase the anticoagulant activities of Dalteparin.Experimental, Nutraceutical
ParecoxibParecoxib may increase the anticoagulant activities of Dalteparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
ParomomycinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Dalteparin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Dalteparin.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Dalteparin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Dalteparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Dalteparin.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Dalteparin.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Dalteparin.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Dalteparin.Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Dalteparin.Approved, Withdrawn
Potassium CitrateDalteparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Dalteparin.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Dalteparin.Approved
ProgesteroneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Dalteparin.Experimental
PromegestoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Dalteparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PropafenoneThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Propafenone.Approved
PropranololThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Dalteparin.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Dalteparin.Experimental
Protein CDalteparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanDalteparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDalteparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Dalteparin.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Dalteparin.Approved
QuingestanolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Quingestanol.Experimental
RamatrobanRamatroban may increase the anticoagulant activities of Dalteparin.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Dalteparin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Dalteparin.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Dalteparin.Approved, Investigational
ReviparinDalteparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Dalteparin.Approved
RivaroxabanDalteparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
SacubitrilDalteparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Dalteparin.Approved
Salicylic acidThe risk or severity of bleeding can be increased when Salicylic acid is combined with Dalteparin.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Dalteparin.Approved
SaprisartanDalteparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinDalteparin may increase the hyperkalemic activities of Saralasin.Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Dalteparin.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Dalteparin.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Dalteparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Dalteparin.Approved
SemapimodSemapimod may increase the anticoagulant activities of Dalteparin.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Dalteparin.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Dalteparin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
Sodium CitrateThe risk or severity of bleeding can be increased when Dalteparin is combined with Sodium Citrate.Approved, Investigational
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Dalteparin.Approved
SRT501SRT501 may increase the anticoagulant activities of Dalteparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Dalteparin.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Dalteparin.Approved
SulfasalazineThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Dalteparin.Approved
SulindacThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dalteparin.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Dalteparin.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dalteparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dalteparin.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Dalteparin.Investigational
TasosartanDalteparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanDalteparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Dalteparin.Approved
TenidapTenidap may increase the anticoagulant activities of Dalteparin.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Dalteparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Dalteparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Dalteparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Dalteparin.Investigational
Testosterone cypionateThe therapeutic efficacy of Dalteparin can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Dalteparin can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Dalteparin can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Dalteparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Dalteparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Dalteparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Dalteparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Dalteparin.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Dalteparin.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Dalteparin.Approved
Tolfenamic AcidThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Dalteparin.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Dalteparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Dalteparin is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Dalteparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TriamtereneDalteparin may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may increase the anticoagulant activities of Dalteparin.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Dalteparin.Investigational
Trolamine salicylateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dalteparin.Approved
TroxerutinDalteparin may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
ValsartanDalteparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VenlafaxineVenlafaxine may increase the antiplatelet activities of Dalteparin.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Dalteparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Dalteparin.Approved
WarfarinWarfarin may increase the anticoagulant activities of Dalteparin.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Dalteparin.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Dalteparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Dalteparin.Withdrawn
Food Interactions
  • Herbs (anticoagulant/antiplatelet properties such as ginseng, ginkgo, ginger, garlic)

References

General References
  1. King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med. 1984 Apr;100(4):535-40. [PubMed:6367579]
  2. Bell WR, Royall RM: Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med. 1980 Oct 16;303(16):902-7. [PubMed:6997743]
  3. Ockelford PA, Patterson J, Johns AS: A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046-9. [PubMed:2559484]
  4. Hartl P, Brucke P, Dienstl E, Vinazzer H: Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577-84. [PubMed:2158151]
  5. Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A: Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol. 1989;37(4):415-8. [PubMed:2557219]
  6. Holmer E, Soderberg K, Bergqvist D, Lindahl U: Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16 Suppl 2:1-7. [PubMed:3744129]
  7. Malm K, Dahlback B, Arnljots B: Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg. 2003 Apr 15;111(5):1659-66. [PubMed:12655212]
  8. Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M: Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006 Jul;91(7):976-9. Epub 2006 Jun 1. [PubMed:16757417]
  9. Schmid P, Brodmann D, Fischer AG, Wuillemin WA: Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009 Apr;7(4):552-8. doi: 10.1111/j.1538-7836.2009.03292.x. Epub 2009 Jan 19. [PubMed:19175499]
  10. Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N: Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007 Feb;46(2):286-94. Epub 2006 Oct 25. [PubMed:17166617]
  11. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
  12. Samama MM, Gerotziafas GT: Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26 Suppl 1:31-8. [PubMed:11011804]
  13. Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]
External Links
KEGG Drug
D03353
PubChem Substance
347910371
Wikipedia
Dalteparin_sodium
ATC Codes
B01AB04 — Dalteparin
AHFS Codes
  • 20:12.04.16 — Heparins

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentAntiphospholipid Syndrome in Pregnancy / Pregnancy Loss1
1CompletedTreatmentClear Cell Sarcoma of the Kidney / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2RecruitingPreventionNeoplasms, Lung / Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCancer of the Ovary1
2CompletedTreatmentEmbolism and Thrombosis1
2CompletedTreatmentMalignant Neoplasm of Pancreas / Thromboembolism1
2CompletedTreatmentShock, Septic1
2CompletedTreatmentSickle Cell Disorders / Vaso-Occlusive Crises1
2CompletedTreatmentVenous Thromboembolism (VTE)1
2Not Yet RecruitingTreatmentBMI >30 kg/m2 / Cancers / Venous Thromboembolism (VTE)1
2Not Yet RecruitingTreatmentCerebral Venous Thrombosis1
2RecruitingTreatmentCancer-associated Thrombosis / Duodenal Cancer / Esophageal Cancers / Hepatobiliary Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
2TerminatedSupportive CareCancers / Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) / Thrombosis / Venous Thromboembolism (VTE)1
2TerminatedTreatmentDeep Vein Thrombosis (DVT) / Neoplasms1
2TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3CompletedPreventionHemodialysis-dependent patients / Thromboembolism1
2, 3CompletedScreeningImpaired Renal Function1
2, 3CompletedTreatmentDiabetic Foot Ulcers (DFU)1
3Active Not RecruitingPreventionStrokes1
3Active Not RecruitingSupportive CareCerebral Vein Thrombosis / Deep Vein Thrombosis (DVT) / Gonadal Thrombosis / Hepatic Thrombosis / Mesenteric Thrombosis / Metastatic Malignant Neoplasm / Neoplasms, Malignant / Portal Vein Thrombosis / Pulmonary Embolism (PE) / Renal Vein Thrombosis / Splenic thrombosis / Venous Thromboembolism (VTE)1
3Active Not RecruitingTreatmentNeoplasms / Venous Thromboembolism (VTE)1
3CompletedPreventionCritical Illness / Deep Venous Thrombosis1
3CompletedPreventionNeoplasms, Brain / Venous Thromboembolism (VTE)1
3CompletedPreventionPostpartum / Venous Thromboembolism (VTE)1
3CompletedSupportive CareCervical Cancers / Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Unspecified Adult Solid Tumor, Protocol Specific / Veno-Occlusive Disease1
3CompletedTreatmentArterial Thromboembolic Events / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentCancer, Breast / Colorectal Cancers / Lung Cancers / Prostate Cancer / Veno-Occlusive Disease1
3CompletedTreatmentChronic Renal Failure (CRF)1
3CompletedTreatmentComplications, Pregnancy / Hypercoagulability / Pregnancy1
3CompletedTreatmentRecurrent Abortion1
3Not Yet RecruitingPreventionTraumatic Brain Injury (TBI)1
3RecruitingTreatmentVenous Thromboembolism (VTE)1
3TerminatedPreventionPulmonary Embolism (PE) / Venous Thromboembolism (VTE)1
3TerminatedTreatmentMalignant Neoplasm of Pancreas / Thromboembolism1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism (VTE)1
3Unknown StatusSupportive CareLung Cancers / Thromboembolism1
4CompletedPreventionArthritis of the Hip / Infection NOS / Transfusion Related Complications / Wound Discharge1
4CompletedPreventionDeep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)1
4CompletedTreatmentCancers1
4CompletedTreatmentCancers / Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)1
4CompletedTreatmentDeep Vein Thrombosis (DVT)1
4CompletedTreatmentLower Extremity Superficial Thrombophlebitis / Superficial Thrombophlebitis / Upper Extremity Superficial Thrombophlebitis1
4CompletedTreatmentLung Cancers1
4CompletedTreatmentMalignant Neoplasm of Pancreas / Venous Thromboembolism (VTE)1
4CompletedTreatmentSuperficial Thrombophlebitis1
4RecruitingPreventionDeep Venous Thrombosis / Pulmonary Embolism (PE)1
4RecruitingPreventionRenal Failure1
4TerminatedNot AvailablePreeclampsia1
4TerminatedPreventionDalteparin / Deep Vein Thrombosis (DVT) / Thromboembolism1
4TerminatedPreventionVenous Thromboembolism (VTE)2
4TerminatedTreatmentMyocardial Infarction / Unstable Angina (UA)1
Not AvailableActive Not RecruitingTreatmentBone Cancer1
Not AvailableCompletedNot AvailableAcute Coronary Syndromes (ACS)1
Not AvailableCompletedNot AvailableAcute Deep Vein Thrombosis1
Not AvailableCompletedNot AvailableBMI >30 kg/m21
Not AvailableCompletedNot AvailableThrombosis, Venous1
Not AvailableCompletedNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableCompletedNot AvailableVenous Thromboembolism (VTE)1
Not AvailableCompletedPreventionThrombophylaxis in Transurethral Surgery1
Not AvailableCompletedPreventionVenous Thromboembolism (VTE)1
Not AvailableEnrolling by InvitationTreatmentAcute DVT of Lower Extremity1
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)1
Not AvailableTerminatedDiagnosticCoagulation, Blood / Compression Devices, Intermittent Pneumatic / Postoperative Complications / Thrombelastography1
Not AvailableTerminatedTreatmentAntiphospholipid Antibody Syndrome / Recurrent Pregnancy Losses1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous10000 [iU]/.4mL
InjectionSubcutaneous10000 [iU]/mL
InjectionSubcutaneous12500 [iU]/.5mL
InjectionSubcutaneous15000 [iU]/.6mL
InjectionSubcutaneous18000 [iU]/.72mL
InjectionSubcutaneous2500 [iU]/.2mL
InjectionSubcutaneous25000 [iU]/mL
InjectionSubcutaneous5000 [iU]/.2mL
InjectionSubcutaneous7500 [iU]/.3mL
SolutionIntravenous; Subcutaneous10000 unit
SolutionIntravenous; Subcutaneous12500 unit
SolutionIntravenous; Subcutaneous15000 unit
SolutionIntravenous; Subcutaneous18000 unit
SolutionIntravenous; Subcutaneous2500 unit
SolutionIntravenous; Subcutaneous25000 unit
SolutionIntravenous; Subcutaneous3500 unit
SolutionIntravenous; Subcutaneous5000 unit
SolutionIntravenous; Subcutaneous7500 unit
LiquidIntravenous; Subcutaneous2500 unit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name
SERPINC1
Uniprot ID
P01008
Uniprot Name
Antithrombin-III
Molecular Weight
52601.935 Da
References
  1. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
  2. Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Vascular endothelial growth factor receptor binding
Specific Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name
VEGFA
Uniprot ID
P15692
Uniprot Name
Vascular endothelial growth factor A
Molecular Weight
27042.205 Da
References
  1. Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS. 2010 Dec;118(12):949-57. doi: 10.1111/j.1600-0463.2010.02635.x. Epub 2010 Oct 12. [PubMed:21091776]
  2. Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637-45. Epub 2007 Aug 10. [PubMed:17692905]
  3. Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action...
Gene Name
TFPI
Uniprot ID
P10646
Uniprot Name
Tissue factor pathway inhibitor
Molecular Weight
35014.835 Da
References
  1. Mousa SA: Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev. 2004 Summer;22(2):121-34. [PubMed:15179449]
  2. Naumnik B, Rydzewska-Rosolowska A, Mysliwiec M: Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study. Clin Appl Thromb Hemost. 2011 Oct;17(5):480-6. doi: 10.1177/1076029610376936. Epub 2010 Aug 3. [PubMed:20682597]
  3. Bendz B, Andersen TO, Sandset PM: Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis. 2000 Jun;11(4):343-8. [PubMed:10847421]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sialic acid binding
Specific Function
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligan...
Gene Name
SELP
Uniprot ID
P16109
Uniprot Name
P-selectin
Molecular Weight
90833.105 Da
References
  1. Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Syndecan binding
Specific Function
Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. Participates in extracellular matrix (ECM) degradation and remodeling. Se...
Gene Name
HPSE
Uniprot ID
Q9Y251
Uniprot Name
Heparanase
Molecular Weight
61148.17 Da
References
  1. Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398]

Drug created on September 14, 2010 10:21 / Updated on August 15, 2018 09:54